Effects of Mirtogenol on ocular blood flow and intraocular hypertension in asymptomatic subjects

Robert D Steigerwalt, Belcaro Gianni, Morazzoni Paolo, Ezio Bombardelli, Carolina Burki, Frank Schönlau, Robert D Steigerwalt, Belcaro Gianni, Morazzoni Paolo, Ezio Bombardelli, Carolina Burki, Frank Schönlau

Abstract

Purpose: The most important variable risk factor for developing glaucoma is intraocular hypertension. Timely lowering of high intraocular pressure (IOP) significantly lowers the likelihood of developing glaucoma. The aim of this study was to evaluate the effects of the food supplement Mirtogenol (Mirtoselect and Pycnogenol on IOP and ocular blood flow in a product evaluation study.

Methods: Thirty-eight asymptomatic subjects with intraocular hypertension were either given Mirtogenol (20 subjects) or were not treated (18 subjects). The visual acuity, IOP, and ocular blood flow were measured at two, three, and six months.

Results: After two months of supplementation with Mirtogenol, the mean IOP decreased from a baseline of 25.2 mmHg to 22.2 mmHg. After three months of treatment with Mirtogenol, the IOP was significantly lowered compared to that of untreated controls (p<0.05) to 22.0 mmHg. No further improvement was found after six months. Nineteen of the twenty patients taking Mirtogenol had a decreased IOP after three months. Only marginal effects on the IOP were found in the 18 control subjects. No side effects were observed. Ocular blood flow (central retinal, ophthalmic, and posterior ciliary arteries) improved both in the systolic and diastolic components as measured by Color Doppler imaging. After three months of treatment, the improvement of ocular blood flow was significant as compared to both baseline and control group (p<0.05).

Conclusions: An improved ocular blood flow may contribute to the prevention of glaucoma. The results of this study indicate that Mirtogenol may represent a safe preventative intervention for lowering the risk for developing symptomatic glaucoma by controlling IOP and improving ocular blood flow.

Figures

Figure 1
Figure 1
The development of intraocular pressure in subjects treated with Mirtogenol®. The asterisk indicates statistical significant difference to the baseline as well as control (p<0.05).

References

    1. Rosenthal BP. Ophthalmology: Screening and treatment of age-related and pathologic vision changes. Geriatrics. 2001;56:27–31.
    1. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363:1711–20.
    1. Christen WG, Liu S, Glynn RJ, Gaziano JM, Buring JE. Dietary carotenoids, vitamins C and E, and risk of cataract in women: a prospective study. Arch Ophthalmol. 2008;126:102–29.
    1. Coleman H, Chew E. Nutritional supplementation in age-related macular degeneration. Curr Opin Ophthalmol. 2007;18:220–3.
    1. Hodge WG, Schachter HM, Barnes D, Pan Y, Lowcock EC, Zhang L, Sampson M, Morrison A, Tran K, Miguelez M, Lewin G. Efficacy of omega-3 fatty acids in preventing age-related macular degeneration: a systematic review. Ophthalmology. 2006;113:1165–72.
    1. Wilkinson-Berka JL, Miller AG. Update on the treatment of diabetic retinopathy. ScientificWorldJournal. 2008;8:98–120.
    1. Perossini M, Guidi G, Chiellini S, Siravo D. Diabetic and hypertensive retinopathy therapy with Vaccinium myrtillus anthocyanosides (Tegens). A double blind placebo-controlled clinical trial. Ann Ottalmol Clin Ocul. 1987;113:1173–90.
    1. Repossi P, Malagola R, De Cadilhac C. The role of anthocyanosides on vascular permeability in diabetic retinopathy. Ann Ottalmol Clin Ocul. 1987;113:357–61.
    1. Schönlau F, Rohdewald P. Pycnogenol for diabetic retinopathy. A review. Int Ophthalmol. 2002;24:161–71.
    1. Kang JH, Pasquale LR, Willett W, Rosner B, Egan KM, Faberowski N, Hankinson SE. Antioxidant intake and primary open-angle glaucoma: a prospective study. Am J Epidemiol. 2003;158:337–46.
    1. Coleman AL, Stone KL, Kodjebacheva G, Yu F, Pedula KL, Ensrud KE, Cauley JA, Hochberg MC, Topouzis F, Badala F, Mangione CM. Study of osteoporotic fractures research group. Glaucoma Risk and the Consumption of Fruits and Vegetables Among Older Women in the Study of Osteoporotic Fractures. Am J Ophthalmol. 2008;145:1081–9.
    1. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, 2nd, Wilson MR, Gordon MO. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13.
    1. Steigerwalt RD, Jr, Laurora G, Belcaro GV, Cesarone MR, De Sanctis MT, Incandela L, Minicucci R. Ocular and retrobulbar blood flow in ocular hypertensives treated with topical timolol, betaxolol and carteolol. J Ocul Pharmacol Ther. 2001;17:537–44.
    1. Allingham RR, Shields MB. Shields' textbook of glaucoma. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
    1. Baudouin C, Liang H, Hamard P, Riancho L, Creuzot-Garcher C, Warnet JM, Brignole-Baudouin F. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology. 2008;115:109–15.
    1. Airaksinen PJ, Alanko HI. Vascular effects of timolol and pilocarpine in the iris. A simultaneous bilateral fluorescein angiographic study. Acta Ophthalmol (Copenh) 1983;61:195–205.
    1. Diggory P, Diggory P, Franks WA. Glaucoma therapy may take your breath away. Age Ageing. 1997;26:63–7.
    1. Tsai JC. Influencing ocular blood flow in glaucoma patients: the cardiovascular system and healthy lifestyle choices. Can J Ophthalmol. 2008;43:347–50.
    1. Liu JH, Kripke DF, Twa MD, Hoffman RE, Mansberger SL, Rex KM, Girkin CA, Weinreb RN. Twenty-four-hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci. 1999;40:2912–7.
    1. Virno M, Pecori Giraldi J, Auriemma L. Antocianosidi di mirtillo e permeabilità dei vasi del corpo ciliare. Boll Ocul. 1986;65:789–95.
    1. Galvano F, La Fauci L, Vitaglione P, Fogliano V, Vanella L, Felgines C. Bioavailability, antioxidant and biological properties of the natural free-radical scavengers cyanidin and related glycosides. Ann Ist Super Sanita. 2007;43:382–93.
    1. Morazzoni P, Bombardelli E. Vaccinium myrtillus L. Fitoterapia. 1996;67:3–29.
    1. Orsucci PL, Rossi M, Sabbatini G, Menci S, Berni M. Trattamento della retinopatia diabetica con antocianosidi. Indagine preliminare. Clin Ocul. 1983;4:77–81.
    1. Caselli L. Clinic, electroretinographic trial on the action of anthocyanosides. Arch Med Interna. 1985;37:29–35.
    1. Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol®), a herbal medication with a diverse pharmacology. Int J Clin Pharmacol Ther. 2002;40:158–68.
    1. Cellini M, Versura P, Zamparini E, Bendo E, Campos EC. Effects of endothelin-1 and flunarizine on human trabecular meshwork cell contraction. Exp Biol Med (Maywood) 2006;231:1081–4.
    1. Schmetterer L, Krejcy K, Kastner J, Wolzt M, Gouya G, Findl O, Lexer F, Breiteneder H, Fercher AF, Eichler HG. The effect of systemic nitric oxide-synthase inhibition on ocular fundus pulsations in man. Exp Eye Res. 1997;64:305–12.
    1. Nishioka K, Hidaka T, Nakamura S, Umemura T, Jitsuiki D, Soga J, Goto C, Chayama K, Yoshizumi M, Higashi Y. Pycnogenol, French maritime pine bark extract, augments endothelium-dependent vasodilation in humans. Hypertens Res. 2007;30:775–80.
    1. Liu X, Wei J, Tan F, Zhou S, Würthwein G, Rohdewald P. Antidiabetic Effect of Pycnogenol® French Maritime Pine Bark Extract in patients with diabetes type II. Life Sci. 2004;75:2505–13.
    1. Colantuoni A, Bertuglia S, Magistretti MJ, Donato L. Effects of Vaccinium Myrtillus anthocyanosides on arterial vasomotion. Arzneimittelforschung. 1991;41:905–9.
    1. Vetrugno M, Sisto D, Trabucco T, Balducci F, Delle Noci N, Sborgia C. Water-drinking test in patients with primary open-angle glaucoma while treated with different topical medications. J Ocul Pharmacol Ther. 2005;21:250–7.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel